UNSPSC 51263301: Nafetolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C19H29NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MAL2XF17MP, chemically known as 1,4-ethanonaphthalen-5-ol, 8-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-, but generally known as nafetolol, which bears US NIH Compound Identifier 68668. European Medicines Agency schedules Nafetolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09121MIG.

UNSPSC 51263301 Nafetolol is a Commodity code nominally identifying a specific pharmaceutical agent, but recent state and local opportunities tagged under it show minimal activity directly related to the code's substance name. The single directly relevant solicitation — Seminole County, Florida's IFB60459723LAS for Naloxone and Safe Drug Deactivation Systems — reflects procurement of naloxone (a distinct opioid antagonist) and drug deactivation equipment for community health support, not nafetolol specifically. The Texas Health and Human Services Commission's RFI HHS0017013 on Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions appears unrelated to the code's nominal pharmaceutical scope and does not identify nafetolol or similar agents as part of its inquiry into pharmacy benefit program restructuring. County health departments and state health agencies are the issuing bodies present in the recent record, though the activity under this code is sparse and does not consistently match the UNSPSC designation.

Geographic activity is limited to Florida and Texas based on the posted opportunities. Seminole County's naloxone procurement (IFB, response due July 26, 2023) represents the only recent solicitation with clear alignment to pharmaceutical product supply, while the Texas HHS RFI (posted April 3, 2026) addresses program design rather than procurement of specific pharmaceutical agents. The mismatch between the code's nominal scope and the actual buying activity suggests either inconsistent coding by issuing bodies or minimal real demand for nafetolol as a named procurement line item in state and local government. Vendors should verify code accuracy directly with issuing authorities before investing in pursuit strategy under this designation.